Captopril is an orally active inhibitor of angiotensin-converting enzyme (ACE) and has been
widely studied in the treatment of patients with mild to moderate essential hypertension …

Few treatments for cardiovascular disease have been shown to have such an impact on
symptoms, morbidity, and mortality as have the angiotensin converting enzyme (ACE) …

The immediate and long‐term effects of enalapril (MK421) and its lysine analogue (MK521)
in once‐daily dosage, were compared in a study of 12 normal subjects. Both compounds …

Enalapril maleate (MK421), a new inhibitor of angiotensin converting enzyme, in single daily
doses of 1.25-40 mg was assessed in five patients with hypertension and renal artery …

The converting enzyme inhibitor enalapril, in single daily doses of 10-40 mg, was given to
20 hypertensive patients with renal artery stenosis. The blood pressure fall six hours after …

The introduction of captopril-the first orally active inhibitor of angiotensin converting enzyme-
into clinical medicine has been an example of skilled, purposeful pharmacological …

The converting enzyme inhibitor enalapril, in single daily doses of 10 to 40 mg, was given to
20 hypertensive patients with renal artery stenosis. The decrease in blood pressure six …

The renin-angiotensin-aldosterone system is inti-mately involved in the regulation of
vascular tone, and is central to sodium homeostasis; the octapeptide angiotensin II, formed …

The investigation of pharmacokinetic and phar-macodynamic relationships after converting
enzyme inhibitors has been limited up until now. The drug most widely available, captopril …

Twenty-seven subjects with essential hypertension were prospectively followed for a
minimum of 100 weeks, receiving either enalapril monotherapy or enalapril and …